MAST1 inhibitors represent a class of compounds designed to selectively target and modulate the activity of Microtubule-Associated Serine/Threonine Kinase 1 (MAST1). MAST1 is a member of the MAST kinase family, playing a crucial role in cellular processes such as cytoskeleton organization, cell division, and intracellular signaling. The inhibitors within this chemical class are specifically engineered to interact with the catalytic domain of MAST1, disrupting its kinase activity. By impeding the phosphorylation of downstream substrates, MAST1 inhibitors exert a regulatory influence on the intricate signaling cascades associated with microtubule dynamics and cellular morphology.
MAST1 inhibitors are meticulously designed to fit into the active site of the kinase, forming specific interactions with key amino acid residues. This binding interaction inhibits the transfer of phosphate groups to target proteins, disrupting the phosphorylation-mediated signaling events orchestrated by MAST1. Researchers focus on elucidating the structure-activity relationships of these inhibitors to optimize their potency and selectivity, aiming to develop compounds that can be valuable tools in unraveling the physiological roles of MAST1. The study and development of MAST1 inhibitors contribute not only to a deeper understanding of cellular processes but also hold promise for potential applications in fields ranging from basic cell biology research to drug discovery efforts targeting conditions associated with dysregulated MAST1 activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent pan-kinase inhibitor. It can inhibit MAST1 by blocking the ATP binding site, thus preventing the phosphorylation process. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor. It inhibits MAST1 by binding to the kinase domain, which disrupts ATP utilization and kinase activity. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib inhibits multiple kinases. It can inhibit MAST1 by preventing the transfer of phosphate groups, thus blocking signal transduction. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum kinase inhibitor. It can inhibit MAST1 by binding to its active site, disabling its enzymatic activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a multi-targeted kinase inhibitor. It can inhibit MAST1 by competing with ATP for the ATP-binding site. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor. It can inhibit MAST1 by blocking the phosphorylation site, thus preventing protein activation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a kinase inhibitor. It can inhibit MAST1 by competing with ATP for the ATP-binding site. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-kinase inhibitor. It can inhibit MAST1 by blocking ATP binding, thus disrupting kinase activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a multi-kinase inhibitor. It can inhibit MAST1 by competing with ATP for the ATP-binding site. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a multi-kinase inhibitor. It can inhibit MAST1 by blocking the ATP binding site, thus preventing the phosphorylation process. | ||||||